<DOC>
	<DOCNO>NCT01350375</DOCNO>
	<brief_summary>This study investigate therapeutic utility BOTOX reduce degree Forward Head Posture ( FHP ) associate headache myofascial pain , decrease frequency headache , improve overall quality life .</brief_summary>
	<brief_title>Safety Efficacy Study Botox Treatment Forward Head Posture With Associated Episodic Headache Disorder</brief_title>
	<detailed_description>This multi-center , prospective , double-blind , placebo-controlled parallel study investigate use BOTOX treatment patient FHP associate headache use novel fix site injection paradigm . Fifteen subject randomize receive BOTOX® fifteen receive placebo injection . Study subject receive one cycle injection , maximal total dosage 250U . The study duration approximately 4 month compose Screening Visit ( Visit 1 , Month -1 ) , Baseline Visit ( Visit 2 , Day 0 ) , three Follow-Up Visits 1 month apart ( Months 1 , 2 3 ) .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Headache</mesh_term>
	<mesh_term>Headache Disorders</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<criteria>1 . Outpatient , healthy male female volunteer race , &gt; 18 year age . Females childbearing potential must negative urine pregnancy test result Baseline Visit practice reliable method contraception throughout study ; A female consider childbearing potential unless : postmenopausal least 12 month prior study drug administration ; without uterus and/or ovary ; surgically sterile least 6 month prior study drug administration . Reliable method contraception : hormonal method must start least 90 day prior study drug administration intrauterine device use &gt; 30 day prior study drug administration ; barrier method plus spermicide use least 14 day prior study drug administration . partner vasectomy least 3 month previously confirmatory 0 sperm count test . Female subject childbearing potential sexually active require practice reliable method contraception . They may enrol Investigator 's discretion provide counseled remain sexually inactive duration study understand possible risk involve get pregnant study . 2 . Diagnosis FHP least twofingerbreadth head forward posture . 3 . Episodic Headache Disorder per follow criterion : &lt; 15 headache day per month include 1014 days/month episodic migraine ( without aura ) ; Chronic migraine exclude ; Chronic Tension type HA exclude . 4 . Subjects able understand requirement participate study , include complete questionnaire , maintain Headache Diary , sign Informed Consent , authorize use/release health research study information . 1 . Pregnant ( positive urine pregnancy test ) , plan become pregnant study period , breastfeeding , childbearing potential practicing reliable contraception . 2 . Patients clinically significant spinal abnormality ( e.g. , scoliosis ) . 3 . Presence cervical dystonia . 4 . Medical condition may increase risk exposure botulinum toxin ( e.g. , Myasthenia Gravis , EatonLambert Syndrome , Amyotrophic Lateral Sclerosis , disease might interfere neuromuscular function ) . 5 . Use aminoglycoside antibiotic , curarelike agent , agent might interfere neuromuscular function . 6 . Injection Site Issues : profound atrophy excessive muscle weakness target area injection , skin problem infection injection site . 7 . Subjects allergy sensitivity component BOTOX® ( Section 5.2 ) . 8 . Evidence recent alcohol/drug abuse . 9 . History poor cooperation , noncompliance medical treatment , unreliability . 10 . Uncontrolled systemic disease , condition situation , investigator 's opinion , may put subject significant risk , confound study result , significantly interfere study participation , and/or life expectancy le 12 month 11 . Participation investigational drug device study within 30 day Screening/Baseline Visit . 12 . Administration BOTOX® within last 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>